Showing 711-720 of 805 results for "".
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- Opthea Discontinues Wet AMD Trials After Another Failed Phase 3 Trialhttps://modernod.com/news/opthea-discontinues-wet-amd-trials-after-another-failed-phase-3-trial/2482721/Just a week after Opthea announced that its combination drug candidate—2 mg sozinibercept combined with 2 mg aflibercept—did not meet its primary endpoint in the COAST phase 3 trial, the company announced similar results with its phase 3 ShORe (Study of OPT-302 in
- Specialty Contact Lens Division WAVE Eye Care Formedhttps://modernod.com/news/specialty-contact-lens-division-wave-eye-care-formed/2482616/EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System—three providers of specialty contact lens fitting—have united to form WAVE Eye Care, a division dedicated to providing fully customized specialty contact lenses. According to a j
- CellViva Appoints Three Ophthalmology Leaders to Board of Directorshttps://modernod.com/news/cellviva-appoints-three-ophthalmology-leaders-to-board-of-directors/2482577/CellViva, a biopharmaceutical company developing anti-vascular endothelial growth factor—anti-VEGF—therapy for pterygium, announced the appointment of three leaders in ophthalmology to its Board of Directors. According to CellViva, the new directors are: Ad
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material
- Microsurgical Technology (MST) Announces Global Partnership with Vista Ophthalmicshttps://modernod.com/news/microsurgical-technology-mst-announces-global-partnership-with-vista-ophthalmics/2482446/Microsurgical Technology (MST) announced an exclusive global partnership with ophthalmic device company Vista Ophthalmics that will introduce Vista Ophthalmics' products—Vista 1-Step and Vista IS—to the global market. Financial terms of the deal were not disclosed.
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di
- ASCRS Launches Summit Designed to Enhance Refractive Cataract Surgery Practiceshttps://modernod.com/news/ascrs-launches-summit-designed-to-enhance-refractive-cataract-surgery-practices/2482384/In a move to enhance the adoption of advanced-technology IOLs (AT IOLs), the American Society of Cataract & Refractive Surgery (ASCRS) announced a new educational initiative—the ASCRS Business of Refractive Cataract Surgery Summit (BRiCS). The summit aims to equip practices with th
- J-Code for Glaukos’ iDose TR Becomes Activehttps://modernod.com/news/cms-j-code-for-glaukos-idose-tr-becomes-active/2482340/Glaukos announced that the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for the company’s iDose TR is effective. The J-code provides patient access and streamlines the coverage and payment process as Glaukos advances its commercial launch of the treatment.<